By Peter M. Prevot, CPA | CEO of Bridge West Consulting
Executive Summary
Minnesota is out of the federal medical cannabis program for now. For most of the state’s operators, that may not be bad news.
On October 30, DEA told a Minneapolis dispensary that Minnesota’s law is a reason it cannot register the business. Four days later, voters gave the DFL full control of state government: preliminary results show 77 of 134 House seats and 39 of 67 Senate seats, with Amy Klobuchar elected governor. Nationally, Democrats won both chambers of Congress. On January 1, the 2026 law merging Minnesota’s medical and adult-use supply chains takes effect.
DEA’s position closes the federal door in Minnesota for now. For the two legacy medical operators, that may be a financial loss with regard to 280E. For the new licensees that make up nearly all of the market, it may be the better near-term outcome.
The federal program is also being tested in court. On November 18, three medical cannabis companies asked a federal appeals court to block DEA’s November 29 supply chain requirement, and more suits are expected. They want a ruling before November 25.
Our view: Minnesota should stay the course and keep developing its market, while its congressional delegation works for a federal system that makes sense for everyone.
This is the first of three updates. Part 1 covers DEA, the litigation and the latest market data. Part 2 covers hemp after December 11. Part 3 covers January 1: the state rules, incentives and deadlines new licensees need to plan around.
How DEA is sorting the states
DEA issued about 900 registrations in its first batch, all in medical-only states: Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia. No adult-use state has a registration. One Virginia medical registrant reported that its registration expires the day before Virginia’s adult-use sales begin; that tells you how DEA sees the two markets.
Applicants are landing in one of three tiers. Some get a full registration. Some get a memorandum of agreement (MOA): DEA registers the business if it agrees to stop a specific practice. The rest get an order to show cause, which means DEA objects to the state program itself.
The dispensary MOAs have been close to identical from state to state. The common terms deal with visiting patients and require a label saying the product may not be transferred to anyone other than the patient. DEA has not agreed to change terms, and no manufacturer MOAs have been reported anywhere.
The show cause orders, mostly sent to dispensaries, have targeted three things so far: enrollment by written recommendation or self-certification (certain Delaware patients over 65, and veterans in Minnesota and Illinois), dual licensing, and synthetic cannabinoids in the supply chain.
Registrations attach to the entity, the state and the license. Some multistate operators have been registered in one state and received a show cause order in another.
The pattern we see in our work is consistent: DEA is not accepting state programs as written. It is checking them feature by feature against its own model, and operators trying to fix a problem still can’t get a clear answer on what a fix looks like.
What the DEA letter said
Minnesota got the third tier. DEA’s letter to In-Dispensary, a Minneapolis microbusiness with a medical retail endorsement, is an order to show cause. It is not a final denial, but it reaches well past one business: DEA wrote that it “cannot permit any applicant operating under” Minnesota’s program.
The order hits all three objections. Dual licensing, because adult-use sales under the same license count as diversion in DEA’s eyes. Veterans enrolling without a practitioner’s written certification. And artificially derived THC, meaning cannabinoids chemically converted after extraction, such as THC made from CBD.
Minnesota takes care of the third one on its own. Starting January 1, artificially derived cannabinoids are barred from medical cannabinoid products (OCM Guidance Memo 2026-09). The first one is a different story: dual licensing is the structure the Legislature chose, and it takes full effect the same day.
In-Dispensary applied around May 27. It has 30 days to respond, with a hearing set for January 19, 2027 if it does. It can withdraw only with good cause and the Administrator’s permission, and it remains a timely applicant until a final denial. It can offer a corrective action plan; DEA has historically not accepted them.
The Office of Cannabis Management (OCM) has said the order does not affect state law, that medical cannabis remains available to patients and that it had received no direct communication from DEA.
Who is affected
Thirty Minnesota businesses filed during DEA’s window: 26 dispensaries, 3 manufacturers and 1 distributor. DEA’s list shows control numbers, not names.
Minnesota’s two legacy medical operators, Rise (Green Thumb Industries) and Green Goods (Vireo Growth), are likely among them. Together they run 16 dispensaries and 3 cultivation and manufacturing sites, which lines up with the counts. Neither company has said what it plans to do here. Vireo announced DEA registrations for all 41 of its Florida dispensaries on November 2; since registrations attach to the state and license, that says nothing about Minnesota.
In-Dispensary shows new licensees applied too, but most of the market never entered the federal process. OCM’s November 2 license file lists 421 cannabis licenses, including 303 microbusinesses, 26 mezzobusinesses and 24 cultivators, operating 250 retail sites. Sixty of those sites carry a medical retail endorsement: 16 belong to the legacy operators and 44 to new licensees.
The legacy operators are still major adult-use players, mostly through their own stores. Vireo reported $19.0 million of Minnesota retail revenue in the second quarter, about a quarter of statewide sales for April through June, with almost no Minnesota wholesale. Green Thumb does not report Minnesota separately.
November 29 and the lawsuits
Starting November 29, timely applicants (businesses that applied between April 28 and June 26 and have not withdrawn or been finally denied) may do business only with registrants or other timely applicants. Due diligence obligations come with it. Getting it wrong risks an order to show cause, denial or revocation.
DEA calls the guidance nonbinding. Attorneys we work with have cautioned against reading that as optional: once you are in the registration process, the enforcement picture changes.
The requirement creates three practical problems. Vertically integrated operators can end up with mixed applicant status across their own licenses. Some states don’t have enough timely applicants to support a full supply chain. And testing labs are not clearly protected.
Minnesota has all three. Its timely applicants include 3 manufacturers and 1 distributor, and no testing labs. Dispensaries may keep selling inventory acquired before October 30; restocking is another matter.
That is what the litigation is about. On November 18, Standard Wellness Utah, Verde Americano (Arizona) and NW Confections OK (Oklahoma) filed a petition for review in the U.S. Court of Appeals for the D.C. Circuit challenging DEA’s October 30 timely applicant guidance (Marijuana Moment). More suits are expected. The petitioners want a stay, or a ruling before November 25; they say they asked DEA to suspend the deadline and got no reply. If a stay is granted, the deadline is paused while the case proceeds. DEA could also withdraw or revise the guidance on its own.
The core argument is simple. The April rescheduling order lets timely applicants keep operating while DEA reviews their applications, with no end date. The November 29 requirement cuts against that, and DEA imposed it as a new rule without notice-and-comment rulemaking. The petitioners also argue DEA ignored the reliance interests it was throwing out. Suits still coming are expected to press reliance harder: DEA opened the dispensary portal during the application window but delayed the manufacturing portal.
The harm claims are specific. One petitioner puts about $275,900 a month in sales at risk; one expects its Oklahoma business to become insolvent; one expects to cut its workforce by 70%. A stay could apply broadly, not just to the petitioners.
No state has joined any of the suits so far. Plaintiffs in the suits still coming are gathering evidence of irreparable harm (customer counts, revenue, documented losses), declarations from state officials on the public health impact, and patient association statements tied to specific supply chains and access gaps. A state with 30 applicants and almost no compliant supply chain is about as clean an example as they will find.
Why staying unregistered may help new licensees
Start with what the 2026 law was for. In 2025 the Legislature directed OCM to propose combining the medical and adult-use supply chains, and OCM delivered its proposal in January of 2026. The bill passed the House 92-42 and the Senate 34-33. Its House sponsor, Rep. Jessica Hanson, said patients had limited access to medical products at just a few companies; Rep. Nolan West described the goal as a market not dominated by a few players (Session Daily).
The law cuts the legacy operators’ canopy from 90,000 square feet to 38,000 under the new macrobusiness license and spreads medical obligations and incentives across the market. Early signals point the way the Legislature intended: medical retail has spread from 16 stores to 60 sites, and registry enrollment rose from about 41,000 to more than 90,000 in the market’s first year.
DEA’s conditions point the other way. A registrable Minnesota medical business would need a separate medical license and supply chain, which in practice describes the two companies that ran the program before adult use began.
For new licensees, sitting outside the federal system while this gets sorted out has real advantages:
- No split federal status. If no Minnesota business is registered, no competitor gains federal standing, or the tax and banking benefits that may follow it, that the rest of the market lacks.
- No closed medical channel. Registrants and applicants may trade only with each other. A handful of registered businesses would form a medical market of their own.
- Ownership rules stay Minnesota’s. DEA’s background and ownership reviews do not track state rules, including those built for social equity applicants, who hold about 43% of Minnesota’s licenses.
- Time. The courts, broader rescheduling and a new Congress are all in play.
OCM’s new guidance cuts both ways. Starting in January, every retail sale is logged in Metrc as a consumer sale or a patient sale tied to a registry number, which answers part of DEA’s diversion concern in state terms. The same memo confirms the design DEA objects to: medical status gets set at the register, not in a separate supply chain.
Minnesota should not re-split its market to fit a federal model that does not recognize state programs as written. It should keep building what the 2026 law set up, and its delegation, now working with Democratic majorities in both chambers, should push for a federal system that makes sense for everyone, including states that chose a single market.
The supply wave
The market keeps growing, and growers are planting far faster than sales. September set a monthly record of $29.4 million, per OCM’s Cannabis Market Monitor. From April to September, adult-use sales rose 43% while medical slipped 7%.
Growers started about 831,000 plants from July through September, roughly 95% of them adult use, and that crop is now coming in. Harvested plants hit 45,835 in August and 73,280 in September. In September 2025 the number was 10,610.
At roughly 90 days from planting to harvest, fourth-quarter harvests should run several times September’s. Sales are growing a few percent a month. Menu prices have held so far; the question for 2027 is what happens to wholesale prices as that crop lands.
|
Measure |
Latest |
Context |
|---|---|---|
|
Trailing 12-month sales |
$272.1M |
4.62M transactions, about $59 per ticket |
|
Monthly sales |
$29.4M in September |
$20.0M adult use, $9.3M medical |
|
Harvested plants |
73,280 in September |
10,610 in September 2025 |
|
Living plants |
504,805 |
111,040 in early June |
|
Median flower price per gram |
$14.19 adult use, $11.38 medical |
Before taxes; menu eighths near $50 since March |
|
Shake and trim share of sales |
15.7% in 2026 |
5.9% in 2024 |
|
Medical sales |
$9M to $10M a month |
Flat all year while enrollment roughly doubled |
OCM labels the data preliminary, and harvest counts are plants, not weight. Part 3 comes back to these numbers.
280E: questions to work through
Minnesota sold about $84 million of medical cannabis from January through September, so the tax treatment of that revenue matters.
Treasury has said relief applies to the full tax year that includes April 22, 2026, that adult-use activity stays under 280E and that allocation guidance for mixed businesses is coming. The qualifying path it named is a state medical license; DEA registration wasn’t mentioned.
We are not taking a position until Treasury publishes that guidance. The questions to work through with your tax advisor now:
- Does a Minnesota license with a medical endorsement count as a state medical license for tax purposes, given DEA’s position?
- How should 2026 costs be split between medical and adult-use activity, and what method will hold up?
- What records should you keep separately after January 1, when the state no longer requires a separate medical supply chain?
- How should financial statements, valuations and cash planning treat relief that may or may not arrive?
What to watch, and the 30 applicants’ choices
|
Date |
What happens |
|---|---|
|
November 19 |
Additional Suits Expected |
|
November 25 |
Date petitioners asked the court to rule by |
|
November 29 |
DEA supply chain requirement takes effect, unless stayed |
|
December 11 |
Federal hemp redefinition takes effect |
|
January 1 |
Minnesota’s merged supply chain and new endorsement rules take effect |
|
January |
New Congress convenes; Minnesota’s 2027 session begins |
|
January 19 |
Scheduled hearing on the In-Dispensary order, if requested |
Minnesota’s 30 timely applicants have a decision to make before November 29, and the right answer depends on whether DEA has already sent them an order.
|
Option |
What it means |
What to weigh |
|---|---|---|
|
Stay in and comply |
Do business only with registrants and timely applicants after November 29, with due diligence |
Whether 3 manufacturers and 1 distributor can supply a store |
|
Withdraw (no show cause order) |
Allowed at any time; ends timely applicant status and its trading limits |
Reapplying appears possible, but the new application must disclose the old one and why it was withdrawn |
|
Respond to a show cause order |
30 days to respond; withdrawal only with good cause and the Administrator’s permission; still a timely applicant until a final denial |
Corrective action plans have historically not been accepted |
|
Wait on the courts |
A stay would pause November 29 while the case proceeds |
Petitioners asked for a ruling by November 25; there is no guarantee it goes the industry’s way |
How we can help
Minnesota’s new licensees are planning for a growing state market, a supply wave about to land and a federal door that is closed for now. We help operators and investors work through those cases with a focus on compliance, from 280E allocation and cash planning to supply contracts and market entry or expansion. Click HERE to schedule a free 15-minute consultation with Peter M. Prevot, CPA
